*Guest blog by Kat Arney, PhD. Founder and Chief Creative Officer, First Create The Media.
If you would like to submit a guest blog please email [email protected].
"The recent biotech funding environment has been horrible."
That was the blunt assessment from Altar Munis from Lifespan Vision Ventures, speaking at a recent Ones To Watch early-stage pitch event run by One Nucleus. I don’t think anyone in the room would have disagreed.
IPOs have been thin on the ground for several years, creating a liquidity crisis. And although there are signs that things are starting to pick up a…
*Guest blog by Professor Alan M. Palmer, Chief Executive Officer, Elixa MediScience.
If you would like to submit a guest blog please email [email protected].
The industry promised AI would transform medicine. Instead, it delivered a speed boost nobody needed and a clinical failure rate nobody fixed.
The pharmaceutical industry has spent the better part of a decade being told that artificial intelligence would transform drug discovery. The pitch was compelling: AI would slash development timelines, cut costs, and defeat diseases that had resisted human ingenuity for generations.…
*Guest blog by Pivotal. For more information on the information in this blog post please contact Natalia Farr - [email protected].
If you would like to submit a guest blog please email [email protected].
Authors: Javier Ortega, Senior Medical Manager | Nicole Mielke, Patient Journey Services & Clinical Operations Director | Leen Mouazen, Business Development Associate at Pivotal
Clinical trials conducted in intensive care units (ICUs) represent one of the most complex and demanding areas of clinical research. Unlike more controlled therapeutic settings, ICUs…
by Tony Jones, CEO, One Nucleus
Email [email protected]
Michael Porter’s Cluster Theory, proposed over 40 years ago, was a watershed explanation of the value of like-minded stakeholders being in close proximity to drive innovation, growth, and in this context, translational research to create better patient outcomes.
The adage that success attracts success has also proven true when one looks at the enviable track record of success from leading international clusters such as Greater Boston, San Francisco, San Diego, Medicon Valley, the United Kingdom…
*Guest blog by LimestoneGrey. If you would like to submit a guest blog please email [email protected].
Protecting Your Business in a Higher-Scrutiny R&D Tax Landscape
R&D tax relief remains a valuable incentive for medtech and life sciences companies investing in genuine scientific and technological advancement. Whether a business is developing medical devices, diagnostic platforms, digital health technologies, therapeutics, clinical tools or advanced healthcare systems, R&D tax relief can provide vital support.
A Changing R&D Tax Relief Landscape
HMRC has significantly…
*Guest blog by Pivotal. For more information on the information in this blog post please contact Ms. Natalia Farr - [email protected]. If you would like to submit a guest blog please email [email protected].
Eva Font, Regulatory and Start-up Director – Pivotal
How sponsors can leverage both the EU Clinical Trials Regulation and UK’s reformed framework to achieve cost efficiencies, faster timelines, and stronger regulatory positioning.
EXECUTIVE SUMMARYThe post-Brexit regulatory landscape has created a unique — and frequently underutilized — opportunity for…
*Guest blog by Romy Frow at Travel Counsellors. If you would like to submit a guest blog please email [email protected].
Business travel has always had a lot of moving parts: flights, hotels, ground transport, budgets and policies. Today, it also means navigating constantly changing geopolitics, airline schedule changes and sudden disruptions, such as the recent events and airspace restrictions in the Middle East.
If you are responsible for multiple travellers, complex itineraries or mission-critical journeys, the stakes are simply too high to leave travel to chance or rely on ad hoc…
*Guest blog by Pivotal. For more information on the information in this blog post please contact Ms. Natalia Farr - [email protected]. If you would like to submit a guest blog please email [email protected].
Transforming Patient Care Through Innovation
Executive Summary
Drug-resistant epilepsy (DRE) affects approximately 15–16 million people worldwide1 — roughly 30% of all individuals with epilepsy. Despite optimal pharmacological therapy, patients experience profound impacts on safety, independence, cognitive function, and survival. The emergence of novel therapeutic agents…
By Monalisa Breazu, Learning & Development Administrator
We recently hosted a seminar on business lead generation from events that sparked a lot of honest conversation around something many businesses know all too well: being busy is not always the same as generating real opportunities.
You can attend the right events, have plenty of conversations, collect a handful of business cards and still come away wondering why none of it turned into actual leads.
One of the strongest themes from the session was that successful lead generation is rarely about saying more. It is usually about saying…
by Philippa Clark, Director of Business Development, One Nucleus
I recently attended a women‑led science event, and it’s one of those occasions that stays with you for reasons you don’t fully expect. It wasn’t a single presentation or statistic that caught my attention, but a theme that kept resurfacing throughout the day and gradually shifted how I was thinking about the whole topic.
For a long time, conversations about women’s health have understandably focused on what’s missing: the gaps in diagnosis, the lack of funding, and the treatments that don’t reflect the realities of women’s…